Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00639158 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 543
- Enrollment target
NCT00639158 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 543 participants.
The verdict
NCT00639158, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 543 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.
Interventions
- DRUG placebo
- DRUG atorvastatin
- DRUG ABT-335
- DRUG ezetimibe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 543 participants |
| Start Date | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00639158
The ClinicalTrials.gov registry entry for NCT00639158 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 543 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00639158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00639158 about?
NCT00639158 is a clinical study titled "Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood". The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.
What is the current status of trial NCT00639158?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 543 participants. The study started on 2008-02.
What interventions are being tested in trial NCT00639158?
The interventions under investigation include: placebo (DRUG), atorvastatin (DRUG), ABT-335 (DRUG), ezetimibe (DRUG).
Who is sponsoring clinical trial NCT00639158?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.